131 related articles for article (PubMed ID: 9403351)
1. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.
Natsis K; Toliou T; Stravoravdi P; Kirtsis P; Grekou A; Barich A; Konstantinidis E; Gigis P
Int J Clin Pharmacol Res; 1997; 17(1):31-6. PubMed ID: 9403351
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
3. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
4. Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy.
Stravoravdi P; Natsis K; Kirtsis P; Retalis G; Konstandinidis E; Polyzonis M
Eur Urol; 1996; 29(4):477-82. PubMed ID: 8791058
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder.
Alvarez-Mon M; Moltó LM; Manzano L; Olivier C; Carballido JA
Anticancer Drugs; 1992 May; 3 Suppl 1():5-8. PubMed ID: 1611117
[TBL] [Abstract][Full Text] [Related]
6. Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-alpha.
Tzai TS; Shiau AL; Wu CL; Chow NH; Tsai YS
Anticancer Res; 1998; 18(5A):3355-61. PubMed ID: 9858908
[TBL] [Abstract][Full Text] [Related]
7. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa.
Stravoravdi P; Toliou T; Kirtsis P; Natsis K; Konstandinidis E; Barich A; Gigis P; Dimitriadis K
J Interferon Cytokine Res; 1999 Mar; 19(3):221-5. PubMed ID: 10213460
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study.
Toliou T; Stravoravdi P; Polyzonis M; Vakalikos J
Eur Urol; 1996; 29(2):252-6. PubMed ID: 8647158
[TBL] [Abstract][Full Text] [Related]
9. Ultrastructural study of the urothelial lysosomal system in patients with transitional cell carcinoma after transurethral resection and interferon therapy.
Stravoravdi P; Natsis K; Kirtsis P; Toliou T; Konstantinidis E; Barich A; Polyzonis M
J Exp Ther Oncol; 1996 Jul; 1(4):222-5. PubMed ID: 9414407
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of natural killer cells in patients with transitional cell carcinoma.
Lin CT; Yu MT; Li C; Ho YC; Shen CH; Liu DW; Chang DC; Wu SF
Cancer Lett; 2010 May; 291(1):39-45. PubMed ID: 19931980
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors.
Carballido J; Moltó LM; Olivier C; Manzano L; Alvarez-Mon M
Anticancer Drugs; 1992 May; 3 Suppl 1():9-12. PubMed ID: 1611118
[TBL] [Abstract][Full Text] [Related]
12. [The ultrastructure of the natural killer cells in transitional-cell bladder cancer].
Gaĭyrov AG
Lik Sprava; 1998; (1):103-6. PubMed ID: 9621630
[TBL] [Abstract][Full Text] [Related]
13. Novel insights into the mechanism of action of intravesical immunomodulators.
Mitropoulos DN
In Vivo; 2005; 19(3):611-21. PubMed ID: 15875784
[TBL] [Abstract][Full Text] [Related]
14. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta enhances the natural killer activity of patients with bladder carcinoma.
Moltó L; Carballido J; Manzano L; Olivier C; Lapeña P; Alvarez-Mon M
Cancer Immunol Immunother; 1994 Jun; 38(6):406-10. PubMed ID: 8205562
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.
Agarwal A; Verma S; Burra U; Murthy NS; Mohanty NK; Saxena S
Cancer Immunol Immunother; 2006 Jun; 55(6):734-43. PubMed ID: 16283306
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma.
Kastelan Z; Lukac J; Derezić D; Pasini J; Kusić Z; Sosić H; Kastelan M
Anticancer Res; 2003; 23(6D):5185-9. PubMed ID: 14981987
[TBL] [Abstract][Full Text] [Related]
18. [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Kälble T; Beer M; Mendoza E; Ikinger U; Link M; Reichert HE; Frangenheim T; Klein E; Fabricius PG
Urologe A; 1994 Mar; 33(2):133-7. PubMed ID: 8178407
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.
Carballido J; Alvarez-Mon M; Solovera OJ; Menéndez-Ondina L; Durántez A
J Urol; 1990 Jan; 143(1):29-33. PubMed ID: 2294256
[TBL] [Abstract][Full Text] [Related]
20. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
Moroz C; Madgar I; Twig S; Lindner A; Many M
Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
